Genovis signs Letter of Intent for the acquisition of CRO company

Genovis, a company based on nanotech, has today signed a Letter of Intent regarding the acquisition of Eijdo research AB. Eijdo is a CRO company specialised in imaging using magnetic resonance. The companies will immediately commence a collaboration which means that Genovis is secured access to specialist know-how and unique equipment The acquisition is intended to be completed through a directed share issue.

– I know that the Eijdo research management team has worked together for several years in the area of contrast media research at Amersham Health/GE Healthcare and lately at Imagnia AB, which is a CRO company. The specialist know-how they possess together with their experience from contract research will strengthen Genovis. The combination Genovis and Eijdo research opens endless possibilities to use the potential of both organizations at maximum, and it reinforces the business model for our products and services in a very competitive manner. I truly look forward to launch this project, says Sarah Fredriksson, CEO Genovis AB. Eijdo research AB provides broad know-how in physics, biology and biochemistry which enables preclinical magnetic resonance (MR) studies that uses equipment of clinical relevance. For example, products intended for clinical use can be evaluated in the early development phase, without spending the substantial costs involved when clinical MR systems are used. – The unique combination of our special competences means new opportunities to bring these biologically interesting nanostructues into the imaging world. Nanotechnology is a new and exciting area for Eijdo, and we see great potential for the technology when used for imaging purposes, says Anna Gisselsson, CEO Eijdo research AB.